Hong Kong-listed Sino Biopharmaceutical Limited (SBP GROUP, 01177) will present 21 new oncology research results at the 2026 Chinese Society of Clinical Oncology (CSCO) Annual Meeting. Five of the studies have been selected for oral presentation, underlining the breadth of the company’s clinical development and real-world evidence (RWE) initiatives across multiple tumour types.\n\nKey Highlights\n• Scope of Research: The submissions span pancreatic, lung, renal, gastrointestinal, soft-tissue, thyroid and breast cancers, as well as desmoid fibromatosis and chemotherapy-induced neutropenia.\n• Assets Featured: One pipeline candidate—IDH1 inhibitor TQB3454—and four commercial products (Anlotinib/Fucove®, Benmelstobart/Andewei®, Efbemalenograstim Alfa/Ryzneuta®, and Penpulimab/Anike®) form the backbone of the data presentations.\n• Oral Presentations (5):\n 1. Phase III trial of TQB3454 in IDH1-mutant advanced cholangiocarcinoma (randomised, double-blind, placebo-controlled).\n 2. ALTER-PA-001 Phase II study comparing Anlotinib + Benmelstobart + AG chemotherapy versus standard AG in first-line metastatic pancreatic cancer.\n 3. Phase II evaluation of Serplulimab + Anlotinib + nab-paclitaxel as second-line therapy for extensive-stage small-cell lung cancer post chemoimmunotherapy failure.\n 4. ETER100 analysis of renal injury in advanced renal cell carcinoma patients treated first-line with Benmelstobart + Anlotinib.\n 5. Retrospective real-world cohort supporting sequential PD-1 therapy after Anlotinib in alveolar soft part sarcoma with lung metastasis.\n\nAdditional 16 Poster/Abstract Presentations\nThe remaining presentations provide clinical data, translational research and health-economic analyses, including:\n• Combination strategies featuring Anlotinib with immunotherapies, targeted agents (e.g., Ensartinib), chemotherapy and radiotherapy in non-small cell lung cancer, small cell lung cancer and pancreatic cancer.\n• Cost-effectiveness comparison of Anlotinib + Penpulimab versus sorafenib in unresectable hepatocellular carcinoma.\n• Exploratory use of Anlotinib in thyroid, breast and soft-tissue sarcomas, plus mechanistic insights into macrophage reprogramming.\n• Comparative study of Efbemalenograstim Alfa against PEG rhG-CSF to prevent chemotherapy-induced neutropenia in nasopharyngeal carcinoma.\n\nStrategic Significance\nThe breadth of indications—spanning early translational work, late-stage trials and RWE—demonstrates SBP GROUP’s multi-asset oncology portfolio and its strategy to expand labels of existing therapies while progressing novel candidates such as TQB3454. Selection of five oral presentations signals peer-recognised scientific relevance ahead of the 2026 CSCO Annual Meeting, scheduled as a key forum for oncology advances in China.\n\nCorporate Governance\nThe announcement was authorised by Chairwoman Ms. Theresa Y Y Tse on 30 July 2026. The Board comprises five executive directors and six independent non-executive directors, maintaining majority independence in line with Hong Kong listing requirements.
Comments